Sort by
Appendix 4C and Quarterly Activities Report - September 2026
IBX Secures Central Ethics Approval - Key Phase 2 Milestone
MagSense Nanoparticle Manufacturing Update
IBX Investor Presentation
Cleansing Notice
Application for quotation of securities - IBX
Application for quotation of securities - IBX
Notification of cessation of securities - IBX
IBX Phase 2 Clinical Trial Update
Change of Director's Interest Notices - RP, BM, NW
| Date | Headline |
|---|---|
8 Oct 2026 | Appendix 4C and Quarterly Activities Report - September 2026 |
30 Sep 2026 | IBX Secures Central Ethics Approval - Key Phase 2 Milestone |
14 Sep 2026 | MagSense Nanoparticle Manufacturing Update |
4 Sep 2026 | IBX Investor Presentation 1 |
1 Sep 2026 | Cleansing Notice |
1 Sep 2026 | Application for quotation of securities - IBX |
1 Sep 2026 | Application for quotation of securities - IBX |
27 Aug 2026 | Notification of cessation of securities - IBX |
26 Aug 2026 | IBX Phase 2 Clinical Trial Update |
25 Aug 2026 | Change of Director's Interest Notices - RP, BM, NW |